Cardiac Biomarker Diagnostic Kits Market Research Report by Disease (Angina Pectoris, Cardiac Heart Failure, and Myocardial Infraction), by Testing (Laboratory Testing and Point of Care Testing), by Product, by End User, by State (California, Florida, and

Cardiac Biomarker Diagnostic Kits Market Research Report by Disease (Angina Pectoris, Cardiac Heart Failure, and Myocardial Infraction), by Testing (Laboratory Testing and Point of Care Testing), by Product, by End User, by State (California, Florida, and Illinois) - United States Forecast to 2026 - Cumulative Impact of COVID-19

The United States Cardiac Biomarker Diagnostic Kits Market size was estimated at USD 570.16 million in 2020 and expected to reach USD 651.56 million in 2021, at a CAGR 11.50% to reach USD 1,095.83 million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.


Market Segmentation & Coverage:

This research report categorizes the Cardiac Biomarker Diagnostic Kits to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease, the market was studied across Angina Pectoris, Cardiac Heart Failure, and Myocardial Infraction.

Based on Testing, the market was studied across Laboratory Testing and Point of Care Testing.

Based on Product, the market was studied across BNP Test Kit, C-reactive Protein (HSCRP), CK-MB Test Kits, Myoglobin Test Kits, and Troponin Test Kits.

Based on End User, the market was studied across Clinics, Diagnostics Centers, and Hospitals.

Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cardiac Biomarker Diagnostic Kits Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Cardiac Biomarker Diagnostic Kits Market, including Abbott Laboratories, Atlas Medical, Beckman Coulter Inc., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., bioMérieux SA, Carlyle Group, Creative Diagnostics, Danaher Corporation, DiaSorin, F. Hoffmann-La Roche AG, Guangzhou Wondfo Biotech, Lepu Medical Technology (Beijing) Co., Ltd., Life Diagnostics, LSI Medience Corporation, MP Biomedicals India Pvt Ltd., PerkinElmer, Inc., Randox Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific, Inc, Tosoh Corporation, and Trivitron Healthcare Private Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Cardiac Biomarker Diagnostic Kits Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Cardiac Biomarker Diagnostic Kits Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Cardiac Biomarker Diagnostic Kits Market?
4. What is the competitive strategic window for opportunities in the United States Cardiac Biomarker Diagnostic Kits Market?
5. What are the technology trends and regulatory frameworks in the United States Cardiac Biomarker Diagnostic Kits Market?
6. What is the market share of the leading vendors in the United States Cardiac Biomarker Diagnostic Kits Market?
7. What modes and strategic moves are considered suitable for entering the United States Cardiac Biomarker Diagnostic Kits Market?


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Introduction
4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Challenges
6. Cardiac Biomarker Diagnostic Kits Market, by Disease
6.1. Introduction
6.2. Angina Pectoris
6.3. Cardiac Heart Failure
6.4. Myocardial Infraction
7. Cardiac Biomarker Diagnostic Kits Market, by Testing
7.1. Introduction
7.2. Laboratory Testing
7.3. Point of Care Testing
8. Cardiac Biomarker Diagnostic Kits Market, by Product
8.1. Introduction
8.2. BNP Test Kit
8.3. C-reactive Protein (HSCRP)
8.4. CK-MB Test Kits
8.5. Myoglobin Test Kits
8.6. Troponin Test Kits
9. Cardiac Biomarker Diagnostic Kits Market, by End User
9.1. Introduction
9.2. Clinics
9.3. Diagnostics Centers
9.4. Hospitals
10. California Cardiac Biomarker Diagnostic Kits Market
11. Florida Cardiac Biomarker Diagnostic Kits Market
12. Illinois Cardiac Biomarker Diagnostic Kits Market
13. New York Cardiac Biomarker Diagnostic Kits Market
14. Ohio Cardiac Biomarker Diagnostic Kits Market
15. Pennsylvania Cardiac Biomarker Diagnostic Kits Market
16. Texas Cardiac Biomarker Diagnostic Kits Market
17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis
17.3. Market Share Analysis, By Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion
18. Company Usability Profiles
18.1. Abbott Laboratories
18.2. Atlas Medical
18.3. Beckman Coulter Inc.
18.4. Becton, Dickinson, and Company
18.5. Bio-Rad Laboratories, Inc.
18.6. bioMérieux SA
18.7. Carlyle Group
18.8. Creative Diagnostics
18.9. Danaher Corporation
18.10. DiaSorin
18.11. F. Hoffmann-La Roche AG
18.12. Guangzhou Wondfo Biotech
18.13. Lepu Medical Technology (Beijing) Co., Ltd.
18.14. Life Diagnostics
18.15. LSI Medience Corporation
18.16. MP Biomedicals India Pvt Ltd.
18.17. PerkinElmer, Inc.
18.18. Randox Laboratories
18.19. Siemens Healthineers AG
18.20. Thermo Fisher Scientific, Inc
18.21. Tosoh Corporation
18.22. Trivitron Healthcare Private Limited
19. Appendix
19.1. Discussion Guide
19.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 3. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: MARKET DYNAMICS
FIGURE 4. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DISEASE, 2020 VS 2026 (%)
FIGURE 5. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DISEASE, 2020 VS 2026 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DISEASE, 2026
FIGURE 7. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY ANGINA PECTORIS, 2018-2026 (USD MILLION)
FIGURE 8. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY ANGINA PECTORIS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 9. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CARDIAC HEART FAILURE, 2018-2026 (USD MILLION)
FIGURE 10. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CARDIAC HEART FAILURE, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 11. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOCARDIAL INFRACTION, 2018-2026 (USD MILLION)
FIGURE 12. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOCARDIAL INFRACTION, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 13. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING, 2020 VS 2026 (%)
FIGURE 14. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING, 2020 VS 2026 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING, 2026
FIGURE 16. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2026 (USD MILLION)
FIGURE 17. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 18. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY POINT OF CARE TESTING, 2018-2026 (USD MILLION)
FIGURE 19. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY POINT OF CARE TESTING, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 20. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PRODUCT, 2020 VS 2026 (%)
FIGURE 21. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PRODUCT, 2020 VS 2026 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PRODUCT, 2026
FIGURE 23. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BNP TEST KIT, 2018-2026 (USD MILLION)
FIGURE 24. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BNP TEST KIT, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 25. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY C-REACTIVE PROTEIN (HSCRP), 2018-2026 (USD MILLION)
FIGURE 26. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY C-REACTIVE PROTEIN (HSCRP), BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 27. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CK-MB TEST KITS, 2018-2026 (USD MILLION)
FIGURE 28. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CK-MB TEST KITS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 29. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOGLOBIN TEST KITS, 2018-2026 (USD MILLION)
FIGURE 30. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOGLOBIN TEST KITS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 31. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TROPONIN TEST KITS, 2018-2026 (USD MILLION)
FIGURE 32. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TROPONIN TEST KITS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 33. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 34. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2020 VS 2026 (USD MILLION)
FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2026
FIGURE 36. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CLINICS, 2018-2026 (USD MILLION)
FIGURE 37. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CLINICS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 38. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DIAGNOSTICS CENTERS, 2018-2026 (USD MILLION)
FIGURE 39. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DIAGNOSTICS CENTERS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 40. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY HOSPITALS, 2018-2026 (USD MILLION)
FIGURE 41. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY HOSPITALS, BY STATE, 2020 VS 2026 (USD MILLION)
FIGURE 42. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: FPNV POSITIONING MATRIX
FIGURE 43. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 44. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DISEASE, 2018-2026 (USD MILLION)
TABLE 5. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY ANGINA PECTORIS, BY STATE, 2018-2026 (USD MILLION)
TABLE 6. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CARDIAC HEART FAILURE, BY STATE, 2018-2026 (USD MILLION)
TABLE 7. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOCARDIAL INFRACTION, BY STATE, 2018-2026 (USD MILLION)
TABLE 8. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING, 2018-2026 (USD MILLION)
TABLE 9. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, BY STATE, 2018-2026 (USD MILLION)
TABLE 10. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY POINT OF CARE TESTING, BY STATE, 2018-2026 (USD MILLION)
TABLE 11. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PRODUCT, 2018-2026 (USD MILLION)
TABLE 12. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BNP TEST KIT, BY STATE, 2018-2026 (USD MILLION)
TABLE 13. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY C-REACTIVE PROTEIN (HSCRP), BY STATE, 2018-2026 (USD MILLION)
TABLE 14. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CK-MB TEST KITS, BY STATE, 2018-2026 (USD MILLION)
TABLE 15. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOGLOBIN TEST KITS, BY STATE, 2018-2026 (USD MILLION)
TABLE 16. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TROPONIN TEST KITS, BY STATE, 2018-2026 (USD MILLION)
TABLE 17. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2026 (USD MILLION)
TABLE 18. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CLINICS, BY STATE, 2018-2026 (USD MILLION)
TABLE 19. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DIAGNOSTICS CENTERS, BY STATE, 2018-2026 (USD MILLION)
TABLE 20. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY HOSPITALS, BY STATE, 2018-2026 (USD MILLION)
TABLE 21. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: SCORES
TABLE 22. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: BUSINESS STRATEGY
TABLE 23. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: PRODUCT SATISFACTION
TABLE 24. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: RANKING
TABLE 25. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 26. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: MERGER & ACQUISITION
TABLE 27. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 28. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 29. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: INVESTMENT & FUNDING
TABLE 30. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 31. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET: LICENSE & PRICING

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook